Prophylactic and therapeutic use of recombinant activated factor VII in patients with cirrhosis and coagulation impairment

Papatheodoridis, 2000, Hemostasis in hepatic and biliary disorders, 199 Mammen, 1994, Coagulation defects in liver disease, Med Clin North Am, 78, 545, 10.1016/S0025-7125(16)30146-8 Rappaport, 2000, Coagulation problems in liver disease, Blood Coagul Fibrinolysis, 11, S69, 10.1097/00001721-200004001-00014 Craxi, 2000, Clinical aspects of bleeding complications in cirrhotic patients, Blood Coagul Fibrinolysis, 11, S75, 10.1097/00001721-200004001-00015 Caldwell, 2004, Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials, Hepatology, 39, 592, 10.1002/hep.20123 Bernstein, 1997, Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study, Gastroenterology, 113, 1930, 10.1016/S0016-5085(97)70013-1 Anantharaju, 2003, Use of activated recombinant human factor VII (rhFVIIa) for colonic polypectomies in patients with cirrhosis and coagulopathy, Dig Dis Sci, 48, 1414, 10.1023/A:1024144217614 Berthier, 2002, Use of recombinant factor VIIa to treat persistent bleeding following dental extractions in two cirrhotic patients, Vox Sang, 82, 119, 10.1046/j.1423-0410.2002.00152.x Lucia, 2001, Successful outcome of a cirrhotic patient with postoperative haematuria treated with a single high dose of recombinant factor VIIa, Haemophilia, 7, 600, 10.1046/j.1365-2516.2001.00568.x Mindikoglu, 2003, Acute intracranial hemorrhage in a cirrhotic controlled with recombinant factor VIIa, Dig Dis Sci, 48, 1130, 10.1023/A:1023777031589 Papatheodoridis, 1999, Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis, J Hepatol, 31, 747, 10.1016/S0168-8278(99)80357-2 Martinowitz, 2005, Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force, J Thromb Haemost, 3, 640, 10.1111/j.1538-7836.2005.01203.x Jeffers, 2002, Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy, Gastroenterology, 123, 118, 10.1053/gast.2002.34164 Bosch, 2004, Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial, Gastroenterology, 127, 1123, 10.1053/j.gastro.2004.07.015 Ejlersen, 2001, Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices, Scand J Gastroenterol, 36, 1081, 10.1080/003655201750422701 Hoffman, 2002, Successful use of recombinant activated factor VII (Novoseven) in controlling severe intra-abdominal bleeding after liver needle biopsy, Thromb Haemost, 87, 346, 10.1055/s-0037-1613000 Quinn, 2004, Severe intraabdominal bleeding post liver biopsy—failure to respond to recombinant factor VII, Thromb Haemost, 91, 632, 10.1055/s-0037-1614290 Erhardtsen, 2000, Pharmacokinetics of recombinant activated factor VII (rFVIIa), Semin Thromb Hemost, 26, 385, 10.1055/s-2000-8457